Because the drug doesn’t target the brain, it has less potential for addiction. Learn why this could help the opioid crisis.

Journavx (suzetrigine) is said to reduce pin by "targeting a pain-signaling pathway involving sodium channels in the ...

Having lived with disabling chronic pain for 32 years, one reader discovered a lesser known treatment that has transformed ...

A non-opioid pain medication made by Vertex Pharmaceuticals has received approval for adults from the Food and Drug ...

The drug, suzetrigine, will be sold under the brand name Journavx and is the first new class of pain medicine approved in ...

Predicting who will transition from acute to chronic pain is the “holy grail” of pain neuroscience. A novel biomarker ...

The Food and Drug Administration Jan. 30 announced it approved Journavx (suzetrigine) oral tablets, a first-in-class ...

On Wednesday, the U.S. Food and Drug Administration approved a new pain management drug which could change the way healthcare ...

Suzetrigine selectively inhibits the NaV1.8 pain-signaling pathway in the peripheral nervous system and provides effective ...